ARS PharmaceuticalsSPRY
About: ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Employees: 160
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
106% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 18
40% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 43
9% more funds holding
Funds holding: 150 [Q3] → 164 (+14) [Q4]
7.26% more ownership
Funds ownership: 66.08% [Q3] → 73.33% (+7.26%) [Q4]
19% less capital invested
Capital invested by funds: $928M [Q3] → $752M (-$176M) [Q4]
26% less call options, than puts
Call options by funds: $2.68M | Put options by funds: $3.65M
67% less funds holding in top 10
Funds holding in top 10: 3 [Q3] → 1 (-2) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Scotiabank Louise Chen 24% 1-year accuracy 28 / 118 met price target | 118%upside $30 | Sector Outperform Initiated | 7 Mar 2025 |
Financial journalist opinion









